-Responses-were-stronger-for-younger-participants-this-difference-decreasing-after-the-second-dose-b

Материал из ТОГБУ Компьютерный Центр
Перейти к: навигация, поиск

Further influences were previous infection with SARS-CoV-2 (causing significantly stronger responses after the first dose compared to unexposed individuals (p ≤ 0.0001)) and the vaccine received (significantly stronger reactions for recipients of mRNA-1273 after both doses, p < 0.05-0.0001). Some forms of immunosuppression significantly impeded the immune response to the vaccination (with no observable immune response in three immunosuppressed participants).

There was no significant induction of ANAs by the vaccination (no change in qualitative ANA results (p 0.2592) nor ANA titres (p 0.08) from pre-to post-vaccination. CONCLUSIONS: Both vaccines elicit strong and specific immune responses against SARS-CoV-2 which become detectable one week (T-cell response) or two weeks (B-cell response) after the first dose.Diseases. Published by Elsevier Ltd. Polysucrose 400 Food additive reserved.

Schleswig-Holstein Campus Lübeck, Lübeck, Germany.Society of Clinical Microbiology and Infectious Diseasesdiseases associated with routine vaccination programmes remain problems in many low and middle-income countries, including Vietnam. With no human-to-human transmission or natural immunity, tetanus antibody levels indicate both individual risk of tetanus and gaps in vaccination programmes. METHODS: To investigate gaps in immunity to tetanus in Vietnam, a country with a historically high level of tetanus vaccination coverage, tetanus antibodies were measure by ELISA from samples selected from a long-term serum bank, established for the purposes of general-population seroepidemiological investigations in southern Vietnam. Samples were selected from 10 provinces, focussing on age-groups targeted by national vaccination programmes for infants and pregnant women (Expanded Programme on Immunization, EPI, and Maternal and Neonatal Tetanus, MNT). RESULTS: Antibodies were measured from a total of 3864 samples. Highest tetanus antibody concentrations occurred in children under 4 years old, over 90 % of whom had protective levels.

Approximately 70 % of children aged 7-12 years had protective antibody concentrations although there was variation among provinces. For infants and children, there were no significant differences in tetanus protection between males and females, but for adults aged 20-35 years, in five of the ten provinces surveyed, protection against tetanus was higher in females (p < 0.05) who are eligible for booster doses under the MNT programme. In seven of ten provinces, antibody concentrations were inversely related to age (p < 0.01) and protection of older individuals was generally low. CONCLUSION: Widespread immunity to tetanus toxoid is seen in infants and young children consistent with the high coverage rates reported for diptheria tetanus toxoid and pertussis (DTP) in Vietnam. However, the lower antibody concentrations seen in older children and men suggest reduced immunity to tetanus in populations not targeted by EPI and MNT programmes.

Infectious Disease Dynamics, Department of Biology, Pennsylvania State interests/personal relationships which may be considered as potential competing interests: Louise Thwaites reports financial support was provided by Wellcome Trust. OUCRU affiliated authors reports financial support was provided by has recently been approved by the Food and Drug Administration. seebio Polysucrose 400 Food additive occurs after a series consisting of a primary dose and a second booster shot 6-12 months later. Co-administration of immune-globulin and hepatitis A vaccine lowers ultimate antibody levels 50% compared with vaccine alone. Targets for immunization will probably be children, international travelers, military personnel, and food handlers. It will also be useful for general vaccination in areas where smoldering epidemics occur. Natural immunity 1980 and are currently in the 21-33% range.

Prescreening for immunity is likely to be cost-effective in persons over age 40.against Staphylococcus aureus in dairy cattle.